| 摘要 |
<p>Compounds of formula (I), in which: R1 is aryl or heteroaryl; R2 is hydrogen, C¿(1-6)?alkyl, arylC(1-4)alkyl, arylC(2-4)alkenyl or C(1-6)alkylcarbonyl; R?3¿ is selected from halo, cyano, hydroxy, (C¿1-6)?alkyl (optionally substituted by halo, hydroxy, amino, carboxy or (C1-6)alkoxycarbonyl), (C3-7)cycloalkyl, C(1-6)alkoxy, amino, mono- or di-(C1-6)alkylamino, acylamino, carboxy, (C1-6)alkoxycarbonyl, carboxy(C1-6)alkyloxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)alkylsulphonyl, carbamoyl, mono- and di-(C1-6)alkylcarbamoyl, and heterocyclyl; m is 0 or an integer from 1 to 3; R?4¿ and a substituent on R1 are linked to form a saturated bridge comprising one or two carbon atoms and a heteroatom selected from O and NR5; R5 is hydrogen or C¿(1-6)?alkyl; Y is a linker group having from 2 to 6 methylene groups in a straight chain and in which one or more alkylene groups may have one or more C(1-6) alkyl substituents and which substituents may be linked to form a C2 or C3 alkylene bridge; Z is NH or O; and salts thereof, preferably pharmaceutically acceptable salts; are inhibitors of Saureus methionyl tRNA synthetase and thereof of use in therapy as antibacterial agents.</p> |
